By Fineline Cube 
Novartis AG (NYSE: NVS) announced that the World Health Organization (WHO) has granted pre-qualification (PQ) status to Coartem® Baby (artemether/lumefantrine), the first and only antimalarial medicine formulated specifically for newborns and small infants weighing 2–5 kg.
Marketed as Riamet Baby in select regions, the dispersible pediatric formulation was co-developed with the Medicines for Malaria Venture (MMV) to address a critical gap in malaria treatment for the most vulnerable population—infants under six months—who historically lacked age-appropriate dosing options.
Product & Public Health Significance
| Feature | Detail |
|---|---|
| Indication | Uncomplicated Plasmodium falciparum malaria in infants 2–5 kg |
| Formulation | Dispersible tablet with precise micro-dosing; sweet-tasting for acceptability |
| WHO PQ Status | Enables procurement by UN agencies (UNICEF, Global Fund) and national programs |
| Development Partnership | Novartis + Medicines for Malaria Venture (MMV) |
| Global Need | ~10 million malaria cases annually in children <5 years; infants at highest risk of severe outcomes |
Novartis’ Broader Global Health Commitment
- Malaria Portfolio: Largest in the industry, including four novel non-artemisinin antimalarial compounds in development to combat rising drug resistance
- R&D Investment: >USD 500 million committed to global health R&D since 2021
- Access Legacy: Delivered over 1.1 billion doses of Coartem since 1999, majority on a not-for-profit basis
- Supply Model: Sells Coartem Baby at cost to public-sector buyers in endemic countries
Strategic & Humanitarian Impact
- Equity Advance: Closes a decades-long therapeutic gap—previously, caregivers often split adult tablets, risking under/over-dosing
- Program Integration: PQ status accelerates rollout through national malaria control programs across sub-Saharan Africa and Southeast Asia
- Innovation Pipeline: Non-artemisinin candidates (e.g., ganaplacide/lumefantrine) aim to provide next-generation tools against artemisinin-resistant strains in the Greater Mekong Subregion
Market Context
While commercial revenue from Coartem Baby is minimal due to its access-oriented pricing, the approval reinforces Novartis’ leadership in responsible innovation and strengthens its partnerships with global health institutions—a strategic asset in ESG-focused investor evaluations and public-sector tender eligibility.
Forward‑Looking Statements
This brief highlights a public health milestone. Distribution scale-up, real-world effectiveness, and pipeline progression remain subject to funding, regulatory approvals, and epidemiological trends.-Fineline Info & Tech